<?xml version='1.0' encoding='utf-8'?>
<document id="15370957"><sentence text="Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats."><entity charOffset="113-126" id="DDI-PubMed.15370957.s1.e0" text="dexamethasone" /></sentence><sentence text="1" /><sentence text=" Cytochrome P450 (CYP) 3A catalysis of testosterone 6beta-hydroxylation in female rat liver microsomes was significantly induced, then reached a plateau level after pretreatment with 80 mg kg(-1) day(-1) dexamethasone (DEX) for 3 days"><entity charOffset="39-51" id="DDI-PubMed.15370957.s3.e0" text="testosterone" /><entity charOffset="204-217" id="DDI-PubMed.15370957.s3.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.15370957.s3.e0" e2="DDI-PubMed.15370957.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15370957.s3.e0" e2="DDI-PubMed.15370957.s3.e1" /></sentence><sentence text=" 2" /><sentence text=" Midazolam was mainly metabolized by CYP3A in DEX-treated female rat liver microsomes from an immuno-inhibition study, and the apparent K(m) was 1"><entity charOffset="1-10" id="DDI-PubMed.15370957.s5.e0" text="Midazolam" /></sentence><sentence text="8 microM, similar to that in human microsomes" /><sentence text=" 3" /><sentence text=" Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0"><entity charOffset="1-13" id="DDI-PubMed.15370957.s8.e0" text="Ketoconazole" /><entity charOffset="18-30" id="DDI-PubMed.15370957.s8.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15370957.s8.e0" e2="DDI-PubMed.15370957.s8.e0" /><pair ddi="false" e1="DDI-PubMed.15370957.s8.e0" e2="DDI-PubMed.15370957.s8.e1" /></sentence><sentence text="088 and 91" /><sentence text="2 microM, respectively" /><sentence text=" The values were similar to those in humans, suggesting that DEX-treated female rat liver microsomes have properties similar to those of humans" /><sentence text=" 4" /><sentence text=" After oral administration of midazolam, the plasma midazolam concentration in DEX-treated female rats significantly decreased compared with control female rats"><entity charOffset="30-39" id="DDI-PubMed.15370957.s13.e0" text="midazolam" /><entity charOffset="52-61" id="DDI-PubMed.15370957.s13.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.15370957.s13.e0" e2="DDI-PubMed.15370957.s13.e0" /><pair ddi="false" e1="DDI-PubMed.15370957.s13.e0" e2="DDI-PubMed.15370957.s13.e1" /></sentence><sentence text=" The area under the plasma concentration curve (AUC) and elimination half-life were one-11th and one-20th of those of control female rats, respectively" /><sentence text=" 5" /><sentence text=" Using DEX-treated female rats, the effect of CYP3A inhibitors on midazolam pharmacokinetics was evaluated" /><sentence text=" The AUC and maximum concentration in plasma (C(max)) increased when ketoconazole was co-administered with midazolam"><entity charOffset="69-81" id="DDI-PubMed.15370957.s17.e0" text="ketoconazole" /><entity charOffset="107-116" id="DDI-PubMed.15370957.s17.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.15370957.s17.e0" e2="DDI-PubMed.15370957.s17.e0" /><pair ddi="false" e1="DDI-PubMed.15370957.s17.e0" e2="DDI-PubMed.15370957.s17.e1" /></sentence><sentence text=" 6" /><sentence text=" It was shown that the drug-drug interaction that occurs in vitro is also observed in vivo after oral administration of midazolam"><entity charOffset="120-129" id="DDI-PubMed.15370957.s19.e0" text="midazolam" /></sentence><sentence text=" In conclusion, the DEX-treated female rat could be a useful model for evaluating drug-drug interactions based on CYP3A enzyme inhibition" /><sentence text="" /></document>